Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Trinity Biotech plc

Market Cap 13.16M 11.37M 10.48M 9.81M 18.38M 1.25B 18.66M 124M 48.23M 609M 49.4M 48.35M 2.11B P/E Ratio 2024
-0.48x
P/E Ratio 2025 -0.39x
Enterprise Value 146M 126M 116M 109M 204M 13.88B 207M 1.37B 535M 6.76B 548M 536M 23.39B EV / Sales 2024
1.8x
EV / Sales 2025 3.37x
Free-Float
96.2%
Yield 2024 *
-
Yield 2025 -
1 day-3.70%
1 week-2.62%
Current month-7.51%
1 month+9.61%
3 months-6.07%
6 months-39.25%
Current year-17.83%
1 week 0.64
Extreme 0.64
0.72
1 month 0.56
Extreme 0.5596
0.75
Current year 0.5
Extreme 0.5012
0.96
1 year 0.5
Extreme 0.5012
3.44
3 years 0.48
Extreme 0.48
5.5
5 years 0.48
Extreme 0.48
16.71
10 years 0.48
Extreme 0.48
68.4
Manager TitleAgeSince
Chief Executive Officer 45 16/12/2023
Director of Finance/CFO - 22/12/2025
Chief Operating Officer - 31/12/1996
Director TitleAgeSince
Chairman 70 30/04/1995
Director/Board Member 67 -
Director/Board Member 45 -
Date Insider Type Main position Quantity % Market Cap.
03-17Other

Chief Executive Officer

980,837 1.1731%
03-17Other

Director

70,004 0.0837%
03-17Other

Founder

895,879 1.0715%
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%-2.62%-3.03%-87.62% 13.16M
+0.55%+4.78%+168.50%+278.98% 17.45B
-1.74%-7.00%-44.69%-25.52% 9.25B
+0.19%+3.51%+30.42%+24.46% 6.8B
-0.17%+8.98% - - 5.08B
-0.39%-2.02%-33.64%-24.80% 5.06B
-2.92%-6.89%-29.54%-31.71% 4.08B
-1.36%-13.84%+63.84%+50.85% 3.77B
-0.72%-7.09%+172.59%-48.36% 3.66B
+0.64%+0.51%-18.74%-41.37% 2.64B
Average -0.96%-1.58%+33.97%+10.55% 5.78B
Weighted average by Cap. -0.45%-0.15%+61.94%+84.36%

Financials

2024 2025
Net sales 61.56M 53.17M 48.99M 45.86M 85.94M 5.85B 87.27M 578M 226M 2.85B 231M 226M 9.86B 43.78M 37.82M 34.85M 32.62M 61.13M 4.16B 62.08M 411M 160M 2.03B 164M 161M 7.01B
Net income -31.79M -27.46M -25.3M -23.68M -44.38M -3.02B -45.07M -299M -116M -1.47B -119M -117M -5.09B -37.38M -32.28M -29.75M -27.85M -52.18M -3.55B -52.99M -351M -137M -1.73B -140M -137M -5.99B
Net Debt 95.6M 82.57M 76.09M 71.22M 133M 9.09B 136M 898M 350M 4.42B 359M 351M 15.31B 133M 115M 106M 98.97M 185M 12.63B 188M 1.25B 487M 6.15B 499M 488M 21.28B
Logo Trinity Biotech plc
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Employees
287
Date Price Change Volume
12/06/26 0.6500 $ -3.70% 86,910
11/06/26 0.6750 $ -1.82% 174,900
10/06/26 0.6875 $ +3.51% 106,271
09/06/26 0.6642 $ -2.32% 150,975
08/06/26 0.6800 $ +1.87% 114,796

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRIB Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!